Detailed Information on Publication Record
2007
Clinical implications of 13q14 and 17p13 deletion, t(4;14) and 1q21 amplification in patients with relapsed multiple myeloma treated by Thalidomide or Bortezomib (Velcade)
KUGLÍK, Petr, Romana ZAORALOVÁ, Hana FILKOVÁ, Henrieta GREŠLIKOVÁ, Pavel NĚMEC et. al.Basic information
Original name
Clinical implications of 13q14 and 17p13 deletion, t(4;14) and 1q21 amplification in patients with relapsed multiple myeloma treated by Thalidomide or Bortezomib (Velcade)
Name in Czech
Klinický význam delece 13q14 a 17p13, translokace t(4;14) a amplifikace 1q21 u relabujících pacientů s mnohočetným myelomem léčených novými typy léků (Thalidomid a Velcade)
Authors
KUGLÍK, Petr (203 Czech Republic, guarantor), Romana ZAORALOVÁ (203 Czech Republic), Hana FILKOVÁ (203 Czech Republic), Henrieta GREŠLIKOVÁ (703 Slovakia), Pavel NĚMEC (203 Czech Republic), Alexandra OLTOVÁ (203 Czech Republic), Luděk POUR (203 Czech Republic), Zdeněk ADAM (203 Czech Republic), M. KREJČÍ (203 Czech Republic) and Roman HÁJEK (203 Czech Republic)
Edition
Netherlands, Chromosome Research, p. 185-186, 2 pp. 2007
Publisher
Springer
Other information
Language
English
Type of outcome
Stať ve sborníku
Field of Study
Genetics and molecular biology
Country of publisher
Czech Republic
Confidentiality degree
není předmětem státního či obchodního tajemství
Impact factor
Impact factor: 3.469
RIV identification code
RIV/00216224:14110/07:00022440
Organization unit
Faculty of Medicine
ISSN
UT WoS
000248859800387
Keywords in English
Multiple myeloma; cIg-FISH; 13q deletion; p53 deletion; t(4;14); amp1q21; Velcade; Thalidomide
Tags
Tags
International impact
Změněno: 30/6/2008 09:54, Mgr. Romana Zaoralová
V originále
The aim of this study was to investigate if Thalidomide or Bortezomib (Velcade) is able to antagonize the impact of negative cytogenetic prognostic markers in patients with relapsed multiple myeloma (MM). We have focused on four chromosomal aberrations known as negative prognostic factors in MM treated by conventional or myeloablative treatment: deletion of 13q14, deletion of 17p13 (p53), translocation t(4;14) and amplification of CKS1B gene (amp1q21). We have identified monotypic plasma cells and studied chromosomal aberrations by cytoplasmic light-chain fluorescence in situ hybridization (cIg-FISH) technique. Two groups of patients with relapsed multiple myeloma of similar age, sex, stage of the disease and other parameters were treated by Thalidomide based regimens (24 patients) and by Bortezomib based regimens (18 patients). In our preliminary experiments, we did not find statistically significant difference in OS and TTP between patients with/without chromosomal aberrations (del p53, t(4;14), ampl 1q21). So it is possible that the new drugs overcome their negative prognostic impact. Patients with 13q14 deletion had significant shorter time to progression median (8.9 month) in comparison with patients lacking RB deletion. Similarly, patients with combination of 3 or 4 of unfavorable cytogenetic abnormalities had significant shorter time to progression median (6.0 month) in comparison with patients with 1 or 2 aberrations These data suggest that cytogenetic abnomalities can define subgroup of patients with relapsed MM not benefiting from Thalidomide and velcade treatment. Data are still preliminary and we need wait for results from large randomized trials.
In Czech
Práce se zabývá klinickým významem přítomnosti delece 13q14, delece genu p53, translokace t(4;14) a amplifikace 1q21 u relabovaných pacientů s mnohočetným myelomem léčených novými typy léků (Thalidomid a Velcade).
Links
| LC06027, research and development project |
| ||
| MSM0021622415, plan (intention) |
|